Trial Information

Summary: A Phase 1 Study of STA-9090, Administered Once-Weekly in Patients with Solid Tumors

A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Once-Weekly in Patients with Solid Tumors

An open-label dose escalation study of patients with solid tumors treated with STA-9090

This is a dose-escalation study. The first cohort will consist of three patients who will receive STA 9090 during a 1-hour infusion once per week for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive higher amounts of STA-9090 provided that the previous dose was well tolerated during cycle 1 (week 1 – 4). Dose escalation will continue until the maximum tolerated dose (MTD) is determined.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:37:35 AM